Gevotroline (WY 47,384) is an atypical antipsychotic compound, which was developed for use in the treatment of schizophrenia. Gevotroline has some clinical efficacy, and equal affinity for D2 (dopamine) and 5-HT2 (serotonin) receptors. Gevotroline was also found to have affinity for sigma receptors, which are thought to be involved in certain neuropsychiatric disorders (because of their ability to regulate the hypothalamic-pituitary-adrenal axis), explaining the interest in this compound for therapeutic use in schizophrenia. Gevoltrine is thought to increase activity in the hypothalamic-pituitary-adrenal axis to elevate levels of corticosterone in plasma. Gevotroline is well tolerated and phase II clinical trials have been conducted, but the compound was never marketed.

Dofequidar (MS-209), a quinolone-derived sphingomyelin synthase inhibitor that blocks P-glycoprotein and multidrug resistance-associated protein-1, is under development by Schering for the potential treatment of multidrug resistant tumors. MS-209 had been in phase III clinical trials for the treatment of breast cancer and non-small lung cancer. But this research was discontinued in 2004. Detected adverse events are: nausea, vomiting, leukopenia, neutropenia, anorexia, constipation.

Proflazepam is benzodiazepine derivative patented by Hoffmann-La Roche, F., und Co., A.-G. as anticonvulsant and muscle relaxant. In preclinical studies, Proflazepam shows activity in pentetrazole test and in the rotating rod test.

Halopenium was studied as an antibacterial and antifungal agent.

Caproxamine is 2-aminoethyl-oxime derivative patented by pharmaceutical company N. V. Philips' Gloeilampenfabrieken as the compound with pronounced action on the central nervous system in doses of 10-500 mg/day for adults.

Rispenzepine (DF 594) is a muscarinic receptor antagonist. Rispenzepine has high affinity for intestinal muscarinic receptors, with preferential action at M1 and M3 receptor subtypes. This drug shows potent inhibitory effects on intestinal motility. In guinea pigs, rispenzepine significantly increases acetylcholine release in the trachea. A phase II study to test efficacy in asthma patients has been discontinued.

Brolaconazole is imidazole derivative with potent antimicrobial activity against pathogenic fungi, molds, yeasts, and Gram-positive bacteria. Brolaconazole showed an inhibition band of 20-40 mM against Candida albican and it demonstrates higher activity compare bifonazole. Brolaconazole is useful for the treatment of dermal and vaginal infections such as vaginal candidiasis, tinea corporis, tinea pedis, tinea cruris, and other dermal infections.

Bremazocine, a kappa-opioid agonist has limited potential as a clinical analgesic, however, possesses a possible utility for the therapy of alcohol and drug addiction. It was shown that bremazocine-like drugs could lower intraocular pressure and to minimize ischemic damage, that could be used in the therapy of glaucoma and cardiovascular disease.

Palytoxin is the most potent marine toxin known that was isolated from a zoanthid of the genus Palythoa and Cyanobacteria (Trichodesmium). Palytoxin is a potent vasoconstrictor that damages the ionic gradient of the cells, causing cell death. This toxin has a strong potential for toxicity in humans and animals that is why it causes great concern worldwide. It is crucial to remove this toxin and start an aggressive topical therapy as soon as possible.

Brufacaine was developed as an antiarrhythmic drug that has never been marketed.